Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

The MMP-2 -735 C Allele is a Risk Factor for Susceptibility to Breast Cancer

  • Yari, Kheirollah (Medical Biology Research Center, Kermanshah University of Medical Sciences) ;
  • Rahimi, Ziba (Medical Biology Research Center, Kermanshah University of Medical Sciences) ;
  • Moradi, Mohamad Taher (Medical Biology Research Center, Kermanshah University of Medical Sciences) ;
  • Rahimi, Zohreh (Medical Biology Research Center, Kermanshah University of Medical Sciences)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The expression of MMP genes has been demonstrated to be associated with tumor invasion, metastasis and survival rate for a variety of cancers. The functional promoter polymorphism MMP-2 C-735T is associated with decreased expression of the MMP-2 gene. The aim of present study was to detect any association between MMP-2 C-735T and susceptibility to breast cancer. Materials and Methods: The MMP-2 C-735T polymorphism was studied in 233 women (98 with breast cancer and 135 healthy controls). All studied women were from Kermanshah and Ilam provinces of Western Iran. The MMP-2 C-735T polymorphism was detected using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The frequencies of MMP-2 CC, CT and TT genotypes in healthy individuals were 59.3, 38.5 and 2.2%, respectively. However, in breast cancer patients, only CC (71.4%) and CT (28.6%) genotypes were observed (p=0.077). In patients the frequency of the MMP-2 C allele was significantly higher (85.7%) compared to that in controls (78.5 %, p=0.048). The presence of C allele of MMP-2 increased the risk of breast cancer by 1.64-fold [OR=1.64 (95%CI 1.01-2.7, p=0.049)]. The frequency of MMP-2 C allele was also higher in patients ${\leq}40$ years (88.9%) than those aged ${\geq}41$ years (67.5%, p=0.07). In addition, the frequency of MMP-2 C allele tended to be higher in patients with a family history of cancer in first-degree relatives (76.6%) compared to that without a family history of cancer (67.3%, p=0.31). Conclusions: Our findings indicate that the C allele of MMP-2 C-735T polymorphism is associated with increased risk of breast cancer. Also, the MMP-2 C allele might increase the risk of young onset breast cancer in our population.

Keywords

References

  1. Babu GR, Samari G, Cohen SP, et al (2011) Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev, 12, 1647-55.
  2. Boroujeni HR, Karimi M, Moshkelani S, Parsaei P (2013) Association of the p53 codon 72 polymorphism with breast cancer in central part of Iran. African J Pharm Pharmacol, 7, 356-9. https://doi.org/10.5897/AJPP12.587
  3. Gai X, Zhang Z, Liang Y, et al (2010). MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clin Chim Acta, 411, 719-24. https://doi.org/10.1016/j.cca.2010.02.002
  4. Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, et al (2012). Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer, 12, 121. https://doi.org/10.1186/1471-2407-12-121
  5. Guo X-T, Wang J-F, Zhang L-Y, Xu G-Q (2012). Quantitative assessment of the effects of MMP-2 polymorphisms on lung carcinoma risk. Asian Pac J Cancer Prev, 13, 2853-6. https://doi.org/10.7314/APJCP.2012.13.6.2853
  6. Hajihoseini S, Bahmani MK, Khosravi A, Ghezelsofla E, Ghaderi A (2011). Prognostic significance of MMP2 and MMP9 functional promoter single nucleotide polymorphisms in head and neck squamous cell carcinoma. Iran J Basic Med Sci, 14.
  7. Hughes S, Agbaje O, Bowen RL, et al (2007). Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clinical Cancer Research, 13, 6673-80. https://doi.org/10.1158/1078-0432.CCR-07-0884
  8. Ke P, Wu Z-D, Wen H-S, et al (2013). Current evidence on associations between the MMP-7 (-181A> G) polymorphism and digestive system cancer risk. Asian Pac J Cancer Prev, 14, 2269-72. https://doi.org/10.7314/APJCP.2013.14.4.2269
  9. Rahimi M, Hasanvand A, Rahimi Z, et al (2010). Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro-and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. Clin Biochem, 43, 1333-9. https://doi.org/10.1016/j.clinbiochem.2010.08.019
  10. Rahimi Z, Rahimi Z, Shahsavandi MO, Bidoki K, Rezaei M (2013). MMP-9 (-1562 C: T) polymorphism as a biomarker of susceptibility to severe pre-eclampsia. Biomark Med, 7, 93-8. https://doi.org/10.2217/bmm.12.95
  11. Rahimi Z, Rahimi Z, Aghaei A, Vaisi-Raygani A (2014). AT2R-1332 G: A polymorphism and its interaction with AT1R 1166 A: C, ACE I/D and MMP-9-1562 C: T polymorphisms: Risk factors for susceptibility to preeclampsia. Gene, 538, 176-81. https://doi.org/10.1016/j.gene.2013.12.013
  12. Rahimi Z, Vaisi Raygani A, Merat A, et al (2006). Thalassemic mutations in southern Iran. Iranian J Med Sci (IJMS), 31, 70-3.
  13. Saeed HM, Alanazi MS, Parine NR, et al (2013). Matrix metalloproteinase-2 (-1306 c>t) promoter polymorphism and risk of colorectal cancer in the Saudi population. Asian Pac J Cancer Prev, 14, 6025-6030. https://doi.org/10.7314/APJCP.2013.14.10.6025
  14. Sanii S, Saffar H, Tabriz HM, et al (2012). Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms. Asian Pac J Cancer Prev, 13, 2175-8. https://doi.org/10.7314/APJCP.2012.13.5.2175
  15. Shagisultanova EI, Novikova IA, Sidorenko YS, et al (2004). The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res, 24, 199-202.
  16. Sharma KL, Misra S, Kumar A, Mittal B (2012). Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Liver Int, 32, 1278-86. https://doi.org/10.1111/j.1478-3231.2012.02822.x
  17. Srivastava P, Kapoor R, Mittal RD (2013a). Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India, Urol Oncol, 31, 247-54. https://doi.org/10.1016/j.urolonc.2011.01.001
  18. Srivastava P, Pandey S, Mittal B, Mittal RD (2013b). No Association of matrix metalloproteinase [MMP]-2 (-735C> T) and tissue inhibitor of metalloproteinase [TIMP]-2 (- 418G> C) Gene polymorphisms with cervical cancer susceptibility. Indian J Clin Biochem, 28, 13-8. https://doi.org/10.1007/s12291-012-0237-4
  19. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70. https://doi.org/10.7314/APJCP.2012.13.1.367
  20. Wang F, Jin X-p, Zhu M, et al (2011). Genotype association of C (-735) T polymorphism of the MMP-2 gene with the risk of carotid atherosclerosis-vulnerable plaque in the Han Chinese population. Vasc Med, 16, 13-18. https://doi.org/10.1177/1358863X10394237
  21. Yadav L, Puri N, Rastogi V, et al (2014). Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev, 15, 1085. https://doi.org/10.7314/APJCP.2014.15.3.1085
  22. Yu C, Zhou Y, Miao X, et al (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res, 64, 7622-8. https://doi.org/10.1158/0008-5472.CAN-04-1521
  23. Zhang Y, Gu Z, Qiu G (2013). Association of the polymorphism of MMP2 with the risk and severity of lumbar disc degeneration in the Chinese Han population. Eur Rev Med Pharmacol Sci, 17, 1830-4.
  24. Zheng L, Zhang Y-M, Zhan Y-Z, Liu C-X (2014). Momordica cochinchinensis seed extracts suppress migration and invasion of human breast cancer ZR-75-30 cells via downregulating MMP-2 and MMP-9. Asian Pac J Cancer Prev, 15, 1105. https://doi.org/10.7314/APJCP.2014.15.3.1105
  25. Zhou P, Du L-F, Lv G-Q, et al (2011) Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 127, 813-8. https://doi.org/10.1007/s10549-010-1294-0
  26. Zhou Y, Yu C, Miao X, et al (2004). Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis, 25, 399-404.

Cited by

  1. Cancer Notification at a Referral Hospital of Kermanshah, Western Iran (2006-2009) vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.133
  2. MMP2 Gene-735 C/T and MMP9 gene -1562 C/T Polymorphisms in JAK2V617F Positive Myeloproliferative Disorders vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.443
  3. Matrix Metalloproteinase-9 -1562T Allele and its Combination with MMP-2 -735 C Allele are Risk Factors for Breast Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1175
  4. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4731-1
  5. Matrix metalloproteinase-2 C-735T and its interaction with matrix metalloproteinase-7 A-181G polymorphism are associated with the risk of preeclampsia: influence on total antioxidant capacity and blood pressure pp.1364-6893, 2017, https://doi.org/10.1080/01443615.2017.1354178